GLP-1s and PCOS: what is approved, and what the trials measured
None of the FDA labels mentions polycystic ovary syndrome. A GLP-1 prescribed for PCOS is prescribed for weight, and the evidence for anything beyond weight is thin.
Do GLP-1 drugs help with PCOS?
They help with weight, which is the part of PCOS they are approved for when BMI qualifies. A 2026 systematic review in the European Journal of Endocrinology pooled 11 randomised trials of GLP-1 drugs added to usual care in women with PCOS and overweight or obesity: BMI fell 1.38 kg/m² more than in the control groups, on low-certainty evidence. For menstrual regularity, hirsutism, glucose and insulin the evidence was insufficient to conclude anything, and no trial measured quality of life or mental health.
Two label facts matter more for PCOS than for most readers, because PCOS is so often also a fertility question. The semaglutide labels say to stop at least 2 months before a planned pregnancy. The tirzepatide labels warn that it can make the pill less reliable for 4 weeks after starting and after each dose increase — relevant to anyone relying on the pill for cycle control and contraception at once.
Last updated 2026-09-02 — the newest FDA label version quoted below. Read and dated by Alex Seot.
The two label facts that bear on PCOS
Neither is about PCOS itself; both are about the pregnancy and contraception questions PCOS usually comes with.
Stop at least 2 months before a planned pregnancy
“Because of the potential for fetal harm, discontinue WEGOVY in patients at least 2 months before they plan to become pregnant to account for the long half-life of semaglutide.”
The pill may fail for 4 weeks after starting and after each dose increase
“Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation.”
Labels that say nothing on it
No label on this site mentions polycystic ovary syndrome:
What the trials measured
11 randomised trials of GLP-1 drugs as an add-on in women with PCOS and overweight or obesity: BMI 1.38 kg/m² lower than control (95% CI 0.38 to 2.39; low certainty). No difference in LDL cholesterol or triglycerides. Insufficient evidence on glucose, insulin, hirsutism and menstrual regularity; no study of quality of life, mental health or cost.
GLP-1s and PCOS, answered
- Is Ozempic or Wegovy approved for PCOS?
- No. Neither label mentions PCOS. Wegovy and Zepbound are approved for weight at a BMI of 30, or 27 with a weight-related condition; a PCOS diagnosis does not qualify on its own, so coverage follows the plan's rules for weight-loss drugs.
- Which is better for PCOS, Mounjaro or Ozempic?
- No trial has compared them in PCOS, and the 2026 review found the PCOS-specific evidence too thin to rank drugs. On weight in general, tirzepatide beat semaglutide head to head in SURMOUNT-5 — 20.2% against 13.7% over 72 weeks — in adults with obesity, not a PCOS population.
- Can a GLP-1 make me more fertile?
- The labels do not claim it, and the 2026 review found too little evidence to say. What the labels do say is practical: tirzepatide can make the pill less reliable after each dose increase, and semaglutide should be stopped 2 months before a planned pregnancy.